Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16863732 | 0.90 | POLB (0.48) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL16605158 | 0.89 | FFAR1 (0.54) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL12660792 | 0.84 | POLB (0.52) | FFAR1NPSR1PTGER4PTGER3FFAR4 | |
| SCHEMBL16605161 | 0.84 | SLC2A1 (0.49) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL69559 | 0.82 | NPSR1 (0.57) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL1892708 | 0.81 | FFAR1 (0.52) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL3670598 | 0.78 | NPSR1 (0.68) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL29636581 | 0.78 | NPSR1 (0.68) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL15959119 | 0.78 | ESR2 (0.56) | FFAR1NPSR1PTGER1PTGER4PTGER3 | |
| SCHEMBL1889009 | 0.78 | FFAR1 (0.54) | FFAR1PTGER1PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN S L (ES) | 2017-07-20 | — | — | US | disclosed |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | FIBROSTATIN, S.L. (ES) | 2015-11-12 | — | — | US | disclosed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN, S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | FFAR1 3034/4885NPSR1 2756/4885PTGER1 2343/4885 |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | FFAR1 3034/4885NPSR1 2756/4885PTGER1 2343/4885 |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | FFAR1 2553/4885NPSR1 3716/4885PTGER1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.